Lv2
174 积分 2025-02-10 加入
Anti-obesity weight loss medications: Short-term and long-term use
1天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
3天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
3天前
已完结
Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning
6天前
已完结
Oral Incretin-Based Therapies for Weight Management
6天前
已完结
Oral GLP-1 Receptor Agonists for Weight Loss
6天前
已完结
Novel oral agents in anti‐obesity pharmacotherapy: A narrative review
7天前
已完结
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
7天前
已完结
Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
10天前
已完结
Stage-specific risk factors of cardiometabolic multimorbidity: A systematic review and meta-analysis from incidence to mortality
10天前
已完结
皖公网安备34019202002308
